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1. Introduction
Type I secretion systems exist in monoderm (sur-
rounded by a single membrane) Gram-positive bac-
teria and diderm (containing both an inner cytoplas-
mic membrane and an outer membrane) Gram-
negative bacteria. They are also called, in the litera-
ture, adenosine triphosphate-binding cassette (ABC)
secretion systems since one of the translocator pro-
tein subcomponents or subdomains is an ABC-AT-
Pase. Type I systems are of interest for studying
ABC transporters involved in an alternative trans-
port pathway responsible for the secretion across
bacterial membranes of a wide range of compounds
(see Table 1). The type I system is also intriguing as a
secretion pathway since it is not limited to translo-
cation across one single bacterial membrane, but ap-
parently achieves movement across the periplasm
and two membranes simultaneously, avoiding lateral
leakage. This article will review the latest aspects of
ABC proteins in Bacteria with an emphasis on pro-
caryotic ABC export systems. Recent results coming
from the work of several laboratories studying the
ABC secretion pathway will then be constructively
analysed with comments upon the techniques and
approaches used. Finally, we aim to integrate the
results into a global picture of what we know about
type I secretion systems.
2. ABC transporters or ABC tra⁄c ATPases
2.1. What de¢nes an ABC transporter/ABC tra⁄c
ATPase?
A highly conserved sequence of approximately 215
amino acids folds into a soluble protein domain
known as an ABC domain or module. It is not our
intention to list all the structural features one ¢nds in
an ABC domain, this being covered elsewhere in this
issue. Of importance, however, are the Walker A and
B motifs common to all nucleotide-binding proteins
and a particular minimum signature sequence, con-
sensus LSGGQ, displayed uniquely by and thus iden-
tifying members of the ABC superfamily [1^4].
At this point it is useful to de¢ne an ABC protein
as distinct from an ABC transporter, since there is an
increasing tendency to use these speci¢c terms inter-
changeably, leading to considerable confusion in the
literature. An ABC protein, refers only to proteins
containing an ATP-binding cassette or ABC-ATPase
domain which is involved in coupling the energy of
ATP hydrolysis to many physiological processes, not
necessarily, but usually, transport related. On the
other hand, an ABC transporter, synonymous with
tra⁄c ATPase (or permease for import systems), is
formed when the cytoplasmic ABC-ATPase associ-
ates with a hydrophobic membraneous domain
(MD), which in most, but not all, ABC transporters
is predicted to form six putative K-helical transmem-
brane segments. An early concept, still not de¢ni-
tively proven, is that ABC transporters possess a
common four^domain arrangement constituted by
homo- or heterodimers of co-operating MD,ABC
units [5,6]. With many ABC transporters, the mem-
brane domain (MD) is fused to the ABC protein,
producing a single MD-ABC unit, which if form-
ing a functional dimer, as is generally supposed,
can be represented as {MD-ABC}2. However, for
many import and export systems, particularly in
bacteria, the MD and ABC protein is formed by
one or two separately encoded membrane proteins
({MD}2{ABC}2). In this case, the membrane protein
might be termed an ABC-dependent transport pro-
tein, or an ABC permease but should not be indi-
cated simply as an ABC protein. Similarly to SecA,
the ATPase of the SecYEG protein translocation
system, the ATP-binding domains of ABC transport-
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Table 1
Examples of the roles and range of allocrites transported by ABC exporters in procaryotes
{MD}2-{ABC}2 con¢gurationa {MD-ABC}2 con¢gurationb
Function ABC trans-
porterc
Allocrite Organism Function ABC
transporter
Allocrite Organism
SDR DrrAB Antitumour antibiotic Streptomyces
peucetius
MDR LmrA Multidrugs Lactotococcus lactis
Immunity
self-protection
NisFEG Nisin lantibiotic Lactococcus lactis Lantibiotic peptides Nis T Nisin precursor Lactotococcus lactis
Peptide antibiotics BsrABC Bacitracin Bacillus licheniformis GG-type bacteriocins,
pheromones
LcnCd Lactococcins
A,B and M/N
Lactotococcus lactis
Teichoic acid TagHG Poly(glycerolphosphate),
poly(glucosegalactosamine
phosphate)
Bacillus subtilis Lipodepsipeptides,
cyclic peptides
SyrD Syringomycin Pseudomonas
syringae
Capsule
polysaccharide
BexABC Polyribosylribitol Haemophilus
in£uenzae
Lipopolysaccharide MsbA Lipid A
precursor
Escherichia coli
Lipopolysaccharide
O-antigen
RfbBA D-Galactan I Klebsiella pneumonia Low molecular
weight carbohydrates
ChvA L-(1^2)-Glucans Agrobacterium
tumefaciens
Lipo-oligosaccharide NodIJ Nodulation factor Rhizobium
leguminosarum
Fatty acylated toxins HlyB HlyA-RTX
toxin
Escherichia coli
Pilin PilHI PilA subunit Myxococcus xanthus Hydrolytic enzymes PrtB Protease Erwinia
chrysanthemi
Exoenzymes EcsAB Exoamylase Bacillus subtilis S-layer capsule LipB SlaA S-protein Serratia marcescens
Haem protein
biogenesis
CcmAB ?e Escherichia coli
aThis con¢guration of ABC exporter normally associates with auxiliary proteins of the MPA-OMA family for the translocation of polymers into or across the exter-
nal cell membrane.
bThis con¢guration associates with auxiliary proteins of the MFP-OMF family for the secretion of allocrites destined for the outer cell surface or the extracellular me-
dium.
cThe four domains of these ABC transporters are expressed on separate polypeptides. In the protein abbreviation used here for the ABC transporter, the ABC do-
main is followed by the MD domain(s).
dThese ABC transporters are equipped with an extra N-terminal cytoplasmic domain involved in proteolytic processing of the peptide allocrite.
eRecent evidence suggests that CcmC is not a subunit of the CcmAB transporter now thought to translocate some component other than haem required for cyto-
chrome c maturation [26].
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ers are thought to undergo complex conformational
changes related to translocation events, inserting
themselves into and across the membrane at least
in some cases [7,8].
ABC transporters are concerned with the transport
across biological membranes of many di¡erent types
of compounds with most bacterial ABC systems
being involved in the import of small solutes, de-
pendent upon a speci¢c binding protein, for example
HisJ, required for histidine uptake [9,10]. A speci¢c
term covering the wide variety of molecules translo-
cated by ABC exporters is lacking. We prefer to use
the term allocrite, loosely derived from the Greek
meaning compounds which are transported. This
avoids the misuse of the word substrate since the
coupling of ATP binding and hydrolysis does not
involve enzymatic modi¢cation of the transported
compound by the ABC transporter. In any case,
the substrate of the ABC-ATPase is ATP.
2.2. Lessons we can learn from phylogenetic analyses
of the ABC superfamily
Thanks to genome-sequencing projects, inventories
of the complete number of ABC-ATPase domains
per genome are now readily available and several
independent attempts have already been made to
classify ABC-ATPases encoded within each micro-
bial genome [11^17]. With the advent of cataloging
the huge ABC superfamily, it is increasingly urgent
to insist upon a standard method for the classi¢ca-
tion of ABC transporters and the adoption of a sys-
tematic convention for the naming of recognised sub-
families. This will prevent later disorder and facilitate
intergenome comparisons.
In Bacteria, it is clear that ABC-ATPases consti-
tute the largest superfamily with some species encod-
ing from 20 to more than 76 di¡erent such proteins
per genome. ABC transporter systems (including the
MD domains and solute binding proteins) account
for at least 5% of all proteins encoded by the Esche-
richia coli and Bacillus subtilis genomes. In the ¢rst
global analysis of the ABC domains recently de-
scribed by Saurin et al. [12], the conclusion is drawn
that an extremely early division occurred within the
ABC-ATPase family, before the di¡erentiation of eu-
caryotes from procaryotes. This primordial division
separates ABC domains according to the direction of
transport, import or export, with which the domain is
concerned. This could re£ect a functional di¡erence
with respect to the action of the ABC domain or the
nature of its interaction with the MD, necessary for
coupling the energy of ATP hydrolysis for either im-
port or export.
In both interkingdom and single genome analyses
of ABC domains, a strong correlation has been
noted between the unrooted trees derived from the
ABC modules and the clustering of the MD modules.
The results indicate that each ABC transporter clus-
ter involves a speci¢c modular organisation of poly-
peptides associated with the transport of a given
group of allocrite. Thus, despite the wide diversity
of compounds transported by the ABC transporter
superfamily, there must be some speci¢city for the
association between the ATPase and a cognate
MD, re£ecting the nature of the corresponding allo-
crite. It is important to note that this concept of
speci¢city can be considered in two ways, taking ac-
count of the highly conserved nature of the ABC
domain and the relative diversity of MDs. The ulti-
mate speci¢city for recognition of allocrites must pre-
sumably be found in the MD or transport domain.
On the other hand, in order to understand the ob-
served clustering of MDs with certain ABC proteins
in phylogenetic studies and therefore the ability of a
universal ATPase to energise a wide variety of trans-
port domains, there must be some built-in speci¢city,
allowing a given ABC-ATPase to recognise its cog-
nate MD.
Given the high degree of conservation of the ABC-
ATPase domain, phylogenetic analysis of this major
superfamily can be extremely instructive, particulary
in relation to the evolution of this ancient family.
The segregation of ABC-ATPases into subfamilies,
especially across kingdoms, is often blurred due to
multiple events of gene duplication, fusion and hor-
izontal gene transfer. The observed di¡erences in al-
locrite speci¢city of evolutionary closely related ABC
systems illustrates how gene duplication allows the
modi¢cation of gene function, via the accumulation
of mutations in one duplicated DNA segment, in
order to provide new metabolic and physiological
diversity to an organism [18]. Examination of the
ABC superfamily also demonstrates how gene fusion
events can contribute to the spread of a protein type.
For example, one ATPase domain may have been
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recruited by more than one integral membrane pro-
tein very early during evolution and these MD-ABC
couples then tended to evolve as a single unit. Exam-
ples also exist of two homologous ABC domains
fused together and separated by a £exible linker,
which have been proposed to hijack di¡erent MD
complexes for function [19]. Finally, examination of
the ubiquitous ABC superfamily should be informa-
tive for comparative analysis of bacteria, archea and
eucaryotes, permitting suggestions concerning evolu-
tionary relationships. For example, di¡erent reper-
toires of ABC proteins are found in di¡erent ge-
nomes. This re£ects in some cases the particular
environment in which an organism has evolved. As
a result of their analysis, Saurin et al. [12] support
the theory that eucaryotes acquired ABC systems
through symbiotic bacteria being the putative ances-
tors of organelles. Nevertheless, despite these in-
sights, the use of the ABC family in this way for
exploring the nature of the ancestral tree has been
poorly developed so far.
3. Some observations and trends: what are ABC
exporters doing in Bacteria?
ABC proteins of bacterial origin appear to per-
form functions a¡ecting processes as diverse as cell
division, regulation of translation elongation of poly-
peptides, to the control of cell volume [20,21]. In
addition of course, ABC systems are essential for
the import of a wide range of low molecular weight
solutes [22]. However, for the purpose of this review,
detailed discussion will be limited to bacterial ABC
transporters involved in export.
Procaryotic ABC exporters display two main types
of packaging of the ABC-ATPase and its cognate
MD module. The domains may be fused into a single
multifunctional polypeptide denoted {MD-ABC}2,
or exist as four separate proteins and denoted then
as {MD}2{ABC}2. In general, each arrangement,
{MD-ABC}2 or {MD}2{ABC}2, is associated with
the export of a speci¢c set of allocrites, although
alternative multidomain polypeptide fusions corre-
sponding to a given ABC transporter and allocrite
can be observed in some genomes. For example,
three types of organisation of antibiotic ABC export-
ers have been described so far, the two arrangements
described previously and an additional combination
with an ATP-binding protein composed of two fused
homologous nucleotide binding domains as in MsrA
(for erythromycin) and OleB (for oleandomycin),
from Staphylococcus epidermidis and Streptomyces
antibioticus [23^25].
The allocrites transported by ABC exporters vary
enormously in their size and aspect. Moreover, many
of the allocrites are post-translationally modi¢ed by
addition of fatty acyl or lipid groups or possess en-
zymatically modi¢ed rare amino acids (lanthionines)
or dehydrated residues (Table 1). Ultimately, it might
be hoped to equate di¡erences in primary sequence
of a given transporter related to its allocrite speci¢c-
ity. This will be especially exciting when further
structural data emerge from crystallography or
NMR studies [27,28]. Happily, arising from the
power of computer-predicted sequence comparisons
and alignments, several family-speci¢c conserved se-
quence motifs have been identi¢ed in ABC and MD
domains associated with the speci¢c transport of sim-
ilar types of compound. The conserved protein mo-
tifs identi¢ed in particular MDs are thought to be
concerned with allocrite recognition, a transmem-
brane signalling process resulting in activation of
the ABC domains or involved in ensuring the vecto-
rial nature of the transported compound (import/ex-
port) [12,29^31]. This clustering of phylogenetically
related ABC or MD domains with very similar allo-
crites helps the assignment of a function to uncharac-
terised ABC transporter orthologues from di¡erent
organisms.
The following sections now represent a brief over-
view of the function of certain classes of bacterial
ABC exporters and their distinguishing features.
3.1. Polysaccharide exporters
A cluster of ABC exporters with ABC-ATPase
domains co-operating with separately encoded simi-
lar or in unusual cases, dissimilar MDs, forming
homo- or hetero-oligomeric channels, have been des-
ignated as ‘ABC-2 transporters’ [29] (see Fig. 1), or
as the subfamily ABC-A2 by Saurin et al. [12]. A
signature motif unique to this cluster is present in
the C-terminal section of at least one or both of
the integral membrane components. In this case, con-
servation probably re£ects the related function of
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these transporters in the transport of a variety of
compounds bearing a glycosylation modi¢cation.
The hydrophilic compounds vary from small drug
molecules (e.g. glycosylated oleondomycin) to com-
plex carbohydrate polymers localised within or on
the surface of Gram-positive and Gram-negative
bacteria (eg. lipopolysaccharide (LPS), teichoic acids
(TCA), capsular polysaccharides (CPS)). Recent ex-
periments suggest that the polymer transport machi-
nery in these cases may associate with the membrane
bound polysaccharide biosynthetic machinery, form-
ing a huge macromolecular complex. Amongst sev-
eral advantages, this would permit the tightly
coupled transport of the polysaccharide chain di-
rectly from its site of synthesis on the cytoplasmic
face of the membrane [32].
3.2. ABC peptide exporters
Gram-positive bacteria produce a plethora of anti-
microbial peptides. Two main classes of antagonistic
peptides are the lantibiotics (class I bacteriocins) con-
taining post-translationally modi¢ed amino acids and
non-lantibiotics (class II bacteriocins), consisting of
unmodi¢ed amino acids [33]. It has been shown for
several of these peptides that their translocation is
mediated by an ABC exporter whose ABC and
MD domains are on the same polypeptide (Table
2). Unusually for compounds transported via ABC
systems, class I and II bacteriocins are synthesised as
precursors containing N-terminal leader peptides,
which di¡er markedly from those of standard secre-
tory proteins, but are, nevertheless, removed during
maturation. The leader peptides of most lantibiotics
(e.g. subtilin, nisin,) are removed after transport
through the ATP transporter by a dedicated pepti-
dase located extracellularly [34]. However, the non-
lantibiotics (e.g. lactococcins, sakacin A) and certain
lantibiotics (e.g. lacticins) with a conserved double-
glycine-type leader peptide (GG-leader), are pro-
cessed concomitantly with secretion by a dual-func-
tion ABC transporter (Table 2). This type of ABC
transporter forms a particular subfamily called the
ABC-containing maturation and secretion (AMS)
protein [34,35]. The hybrid AMS proteins contain
an N-terminal extension of approximately 160 amino
acids forming a proteolytic domain not present in
other ABC proteins. The proteolytic domain is ap-
parently located in the cytoplasm indicating, surpris-
ingly, that processing of the precursors into their
mature form takes place at the cytosolic side of the
cytoplasmic membrane [35]. In addition, AMS ex-
port mechanisms have been observed for the trans-
port of certain competence factors and peptide pher-
Fig. 1. Schematic representation of two types of ABC-dependent transporter complex involved in type 1 secretion (left) or ABC-2-de-
pendent (right) in Gram-negative bacteria. Note that the MFP component which couples here with the ABC transporter and hydroly-
sis of ATP to drive transport, can also couple with other systems such as the MFS and RND family of transporters, driving transport
using the proton motive force. Note also that in Gram-positive bacteria non-lantibiotics, such as lactococcins, are secreted by a type 1
mechanism utilising an ABC transporter plus a member of the MFP family, whilst lantibiotic peptides, such as nisin, require only the
ABC transporter protein.
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Table 2
ABC peptide exporter systems of Gram-positive and Gram-negative bacteria involved in producer self-protection (immunity), processing and/or secretion
Bacteriocin or
allocrite
ABC transporter conferring
immunity{MD}2-{ABC}2 a
ABC transporter of precursor
peptide{MD-ABC}2
Membrane fusion
protein
Outer membrane
factor
Gram-positive bacteria
Class I lantibiotics
FNLDV-type leader sequence Nisin NisFEG NisT
Subtilin SpaFG SpaT
Epidermin EpiFEG EpiT
G-G type leader sequence Lacticin 481 LctFEG LctTb
Mersacidin MrsFEG MrsTb
Class II non-lantibiotics
G-G type leader sequence Sakacin A SapTb SapE
Sakacin P SppTb SppE
Leucocin A LcaCb LcaD
Mesentericin Y105 MesDb MesE
Enterocin A EntTb EntD
Lactococcin A, B,
M/N
LncCb LncD
Lactococcin G/M LagDb LagE
Peptide pheromones Plantaracin A PlnGb PlnH
Competence
peptide
ComAb ComB
Gram-negative bacteria
G-G type leader sequence Colicin V CvaBb CvaA TolC
Microcins B17 McbFEc ? ?
MccJ25 McjDc ?d TolC
aIn the protein abbreviation used here for the ABC transporter, the ABC domain is followed by the MD domain(s).
bRefers to those ABC transporters that are equipped with an extra N-terminal cytoplasmic domain involved in proteolytic processing of the peptide allocrite.
cThe microcin ABC transporters are thought to function in translocation of the precursor and play a role in self-protection.
dThe secretion and export of MccJ25 probably involves an auxiliary membrane fusion protein which remains to be identi¢ed [39].
B
B
A
M
E
M
77704
22-11-99
J.
Y
oung,
I.B
.
H
olland
/B
iochim
ica
et
B
iophysica
A
cta
1461
(1999)
177^200
183
omones also carrying a GG-leader, and responsible
for the production of the bacteriocins in lactic acid
bacteria (LAB), onset of competence in B. subtilis
and other such quorum-sensing modes [36^38].
The production of peptides of this type is not ex-
clusively a phenomenon of Gram-positive bacteria.
Gram-negative Enterobacteriaceae also produce pep-
tide antibiotics. The best characterised from E. coli
include microcins MccB17 and MccJ25, both ex-
ported by ABC transporters [39^41]. The only
known peptide of the double-glycine type in E. coli
is colicin V which is similarly processed and exported
by a hybrid ABC transporter protease. In summary,
the ABC peptide exporters are suitable vehicles for
secretion, rather promiscuous in fact, allowing a
large variety of proteins to be translocated, provided
a recognisable N-terminal region is present, acting as
a secretion signal. As with the polypeptide, C-termi-
nal signal dependent, transport mechanism for ABC
transporters, essentially nothing is known of the
structural requirements of peptides necessary for suc-
cessful transport through the translocator [42].
3.3. ABC drug exporters
ABC drug transporters are responsible for single
drug resistance (SDR) in Gram-positive bacteria, and
these are speci¢c for transporting a single or a group
of closely related drugs. Nearly all SDR transporters
show a variation of the {MD}2{ABC}2 arrangement
[25]. Only one bacterial ABC drug transporter con-
ferring multidrug resistance (MDR) has been exper-
imentally characterised, namely LmrA of the Gram-
positive bacterium, Lactobacillus lactis [43,44]. LmrA
shows an {MD-ABC}2 arrangement. However, the
existence of MDR ABC transporters may be more
widespread than ¢rst realised, with the recent reports
of cryptic MDR systems in genera other than lactic
acid bacteria [45]. Curiously, no functional ABC,
single or multidrug, transporter has yet been de¢ni-
tively established to exist in Gram-negative bacteria.
A few ABC transporters have been suggested to be
putative drug exporters in Gram-negative bacteria on
the basis of some sequence identity with the human
multidrug P-glycoprotein, but experimental evidence
demonstrating any associated drug resistance is still
lacking. In fact, for certain of these ABC transport-
ers, non-drug related functions have since been iden-
ti¢ed, for example MsbA, involved in the transport
of lipids to the inner surface of the outer membrane
of E. coli [46]. The lack of ABC antibiotic and drug
resistance systems in Gram-negative bacteria is fur-
ther highlighted by the relatively frequent occurrence
of such ABC exporters encoded by the B. subtilis
genome [11]. This raises interesting questions, such
as why was there an expansion or retention of ABC
exporters conferring drug resistance in Gram-positive
bacteria? Perhaps ABC drug exporters in Gram-neg-
ative bacteria are redundant in the face of many
alternative secondary transporter drug e¥ux systems
of extremely ancient origin. In contrast, drug e¥ux
pumps of the ABC-type appear to be recent acqui-
sitions to genomes and have appeared only occasion-
ally during the evolution of this superfamily [47].
In fact, the in vivo role and therefore the true
physiological reason for the appearance of ABC mul-
tidrug transporters is of some dispute [48]. In both
eucaryotes and procaryotes, it is still not clear
whether removing toxic chemicals from the cell is
the true physiological function of MDR systems.
Rather, this capacity to transport drugs may re£ect
an adaptation from a more speci¢c role in the trans-
port of unidenti¢ed endogenous molecules, such as
lipids. Indeed, for major MDR systems in mammals,
lipids have been shown to be physiological allocrites
[49^51]. Thus, MDR systems may have developed to
provide a selective advantage against biocides or
have evolved to provide self-resistance to toxic me-
tabolites produced by the microorganism itself. In
this context, it is important to analyse bacterial
ABC exporters known to be involved in self-resist-
ance to small peptide bacteriocins.
3.4. ABC exporters involved in producer
self-protection
Bacteria producing antimicrobial peptides also
have to be protected from the lethal e¡ects of these
compounds. In some cases, as for the colicins pro-
duced by Gram-negative bacteria, this can be
achieved by a speci¢c immunity protein, synthesised
by the colicin producer, as an integral membrane
protein possessing three to four transmembrane do-
mains. The immunity protein binds to the pore-form-
ing domains of the corresponding colicin to block the
action of either outgoing or incoming colicin picked
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up from the medium [52]. Amongst several mecha-
nisms proposed to operate for immunity to class I
lantibiotics (e.g. subtilin, nisin, lacticin 481) pro-
duced by Gram-positive bacteria, one is a quite dif-
ferent mechanism appearing to involve active extru-
sion [53]. In this case, another ABC exporter is
required for the re-translocation of those exported
peptides that have penetrated the membrane from
the external medium. The vast majority of such im-
munity ABC exporters are encoded by two (spaFG)
or three (nisEFG, lctEFG) subunits constituting
homo- or heterodimers of the membrane spanning
unit. Whilst the ABC-ATPase in these systems are
highly homologous, the MDs show few sequence
identities (about 20^30%) [54^56].
The ABC peptide exporters involved in producer
self-protection have the same {MD}2{ABC}2 organ-
isation as certain other ABC transporters that pro-
vide resistance to peptide antibiotics and drugs, for
example, the Bcr bacitracin transporter of Bacillus
licheniformis and the Drr system for export of dau-
norubicin by Streptomyces peucetius [57,58] (Table
1). Almost nothing is known about the mechanism
of immunity conferred by ABC peptide exporters to
membrane damaging peptide antibiotics. This is pre-
sumed to involve removal of the bacteriocin from its
target within the bilayer and its expulsion to the
surrounding medium, thus preventing accumulation
in the membrane [54,57]. This mechanism of inter-
ception of hydrophobic compounds in the bilayer
and their elimination from the inner lea£et by a ‘£ip-
pase’ or a ‘vacuum cleaner’ mechanism, is of course
the favoured mechanism for the action of multi-drug
resistance transporters. Much of the evidence for this
mechanism is based on studies using LmrA of L.
lactis, which has an {MD-ABC}2 transporter organ-
isation [59].
The ABC transporters of the lantibiotic immunity
systems are encoded within the same operon as the
genes involved in the biosynthesis and export of lan-
tibiotics (see Section 3.2). That two specialised ABC
transporters are involved, respectively, in secretion of
the precursor or in immunity to the mature form of
the exported allocrite, raises questions concerning the
speci¢city and capacity of each transporter to recog-
nise its particular form of the allocrite. There is no
homology between these respective transporters
which in addition are con¢gured di¡erently, the
MD and ABC domains of the ABC exporter in-
volved in transport of the lantibiotic precursor being
constituted from a single {MD-ABC}2 polypeptide.
Surprisingly, in Gram-negative producers of micro-
cins B17 and J25, the same ABC transporter is
thought to function both in export and immunity
[39,41].
4. Further transport across procaryotic membranes
At least some ABC exporters may expel drugs and
peptide lantibiotics across a single membrane, the
cytoplasmic membrane, and therefore no additional
proteins are involved (see Table 2). However, ABC
exporters transporting allocrites destined for the out-
er membrane of Gram-negative bacteria, the cell sur-
face of Gram-positive and Gram-negative bacteria or
the extracellular medium, often if not invariably re-
quire the presence of additional auxiliary compo-
nents to complete the transport pathway. In some
cases, the allocrites may be passed on to separate
transport systems independently of the ABC trans-
porter. In other cases, however, the auxiliary proteins
(sometimes called helper or accessory proteins) are
indispensable to the function of the ABC transporter
and together form an integral export unit. Two dis-
tinct types of auxiliary protein units have been char-
acterised and designated (sometimes unfortunately
misleading) family names by Saier and colleagues
[60^63]. Each type is considered distinct through
their relative topology and through their association
with a particular subclass of ABC exporter and
therefore di¡erent allocrite. In other words, each
ABC-dependent exporter unit appears to be tailor
made to suit a de¢ned allocrite as illustrated in
Fig. 1.
Thus, subunits of ABC exporters encoded by sep-
arate genes ({MD}2{ABC}2) and belonging to the
aforementioned ABC-2 (ABC-A2) transporter fam-
ily, associate with inner membrane auxiliary proteins
designated the membrane periplasmic auxiliary
(MPA) family. An additional subclass of outer mem-
brane protein, the outer membrane auxiliary (OMA)
family, is required by these systems in Gram-negative
bacteria. The {MD}2{ABC}2-MPA-OMA secretion
systems are largely involved in the biogenesis of the
bacterial cell surface, transporting cell wall compo-
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nents and complex carbohydrate polymers of the cell
surface, such as LPS and CPS (Fig. 1). In contrast,
fused {MD-ABC}2 ABC transporters associate with
inner membrane auxiliary proteins of the membrane
fusion protein (MFP) family, with an additional out-
er membrane factor (OMF) auxiliary protein re-
quired to complete transport across the outer mem-
brane in Gram-negative bacteria. This multicom-
ponent ATP driven transport system, {MD-ABC}2-
MFP-OMF, forms a transenvelope structure known
as the type I or ABC-dependent secretion system
(Fig. 1). The genetic determinants of type I systems
are frequently plasmid-borne and often form part
of an operon. Type I secretion systems are partic-
ularly relevant to the pathogenic properties of
strains, since this is also used for secretion of toxins,
degradative enzymes and various cell surface protec-
tive structures, as will be described in the next sec-
tion.
4.1. ABC exporters of type I systems transport
polypeptides and non-proteinaceous material
ABC transporters of type I secretion systems pro-
vide an energised ATP-dependent transport pathway
for proteins localised to the surface of the bacterial
outer membrane or released as soluble proteins into
the extracellular medium. Proteins remaining associ-
ated with the cell surface include certain glycanases
and the protective S-layer protein. Soluble extracel-
lular proteins include examples, such as hydrolytic
enzymes (metallo-proteases, lipases), haem-binding
scavenger proteins (HasA, FrpA) and pore-forming
toxins (haemolysins, leukotoxins) [64].
Two distinctive features unify these diverse allo-
crites of type I secretion systems. Most, but not all,
the allocrites secreted via this pathway are classi¢ed
as repeats in toxin (RTX) Ca2-binding proteins.
This is attributable to a variable number of glycine-
rich RTX nonapeptide motifs which fold to form a
L-roll structure which binds calcium ions [65]. In
some cases, the RTX repeats appear to be required
for e⁄cient secretion through the transport appara-
tus, especially for large, heterologous proteins [65^
67]. Secondly, with few exceptions, secretion is de-
pendent upon a non-cleaved secretion signal located
at the C-terminus of the polypeptide. Comparison of
the C-terminii reveals poor conservation at the pri-
mary sequence level except for a 4^6 residue motif at
the extreme end which allows division of the alloc-
rites into three subfamilies: HlyA-like, metallopro-
tease-like and others [68,69]. Exceptionally HasA, a
comparatively small type I allocrite (19 kDa), lacks
the RTX-Ca2-binding repeats and possesses a C-
terminal signal sequence which is cleaved after secre-
tion [70].
Although, type I export systems usually involve
the ATPase fused to the C-terminal of the membrane
domain, notation {MD-ABC}2, there may be excep-
tions to this, such as the recently discovered DevB-
CA exporter, encoding an ABC transporter with an
apparent {MD}2{ABC}2 arrangement, associated
with an MFP/OMF [71]. The ABC exporters of the
membrane-targeted HlyA-related toxins (HlyB,
CyaB, LktB) constitute a sub-group distinct from
the ABC metalloprotease exporters. Surprisingly, in
this subclass the ABC component at least is more
closely related to ABC-ATPases of exporters con-
cerned with the transport of lipophilic drugs (e.g.
LmrA), lipids (e.g. MsbA), polysaccharides (e.g.
HetA) and the highly substituted carbohydrate rich
L-1,2-glucans (e.g. NdvA and ChvA) [12]. This last
allocrite is found almost exclusively in bacteria of the
Rhizobiaceae family, being important for symbiosis
and nodule invasion. The common factor that may
link these ABC exporters of which HlyB is the pro-
totype, is that their function all involve transport of
allocrites of a lipidic nature. HlyA-like toxins are
post translationally modi¢ed with two fatty acid ad-
ditions, L-glucans for example are non-proteinaceous
allocrites. However, at least in the case of HlyA,
acylation of the toxin is not apparently involved in
any way in the secretion mechanism [72]. Type I
secretion transporters are intriguing in another way,
with their ABC domain phylogenetically the closest
amongst the bacterial ABC proteins to the TAP1/2
(peptide transporter) and Mdr (for example P-glyco-
protein) found in mammals, including humans
[12,72].
4.2. What does the integral transmembrane channel of
the ABC polypeptide transporters look like?
Considerable reference has been made to the ABC
exporters of type I systems in connection with their
similarity to the two extensively studied eucaryotic
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ABC transporters: the heterodimeric TAP1/2 trans-
porter associated with antigen presentation and hu-
man Mdr1 (Pgp), responsible for the resistance of
cells to several unrelated drugs, but also implicated
in lipid transport. This similarity is based on the
surprisingly close relationship of the ABC-ATPase
of HlyB to these proteins in phylogenetic analyses
[12], but also extends to signi¢cant similarity detected
between the distal regions of the MD of HlyB and
Pgp [31,71^73].
ABC polypeptide transporters also share with the
TAP and Mdr ABC exporters a limited ability to
recognise and transport heterologous allocrites.
This includes other RTX-proteins but also colicin
V in the case of HlyB. For Pgp a variety of trans-
ported allocrites have been reported, including the
yeast mating pheromone [74]. Attempts to map al-
locrite recognition sites in each of these ABC trans-
porters has given rise, as with other ABC transport-
ers, to the idea of an allocrite binding site located
within the membrane domain and a translocation
mechanism, involving in this case peptide or poly-
peptide induced intramolecular signalling to activate
the ATPase, with consequent release of energy for
transport. E¡orts to de¢ne the steric limits of the
binding site of these transporters and residues in-
volved in allocrite selection has had limited reward
so far [75,76].
The arrangement of the K-helical transmembrane
segments (TMS) of Pgp, TAP and HlyB have been
di⁄cult to analyse and the possibility of the presence
of L-sheet structures cannot be excluded [77]. Current
algorithms appear to predict transmembrane seg-
ments of ABC transporters less well than for other
membrane proteins, such as bacteriorhodopsin, em-
phasising the need for experimental measurement of
the topology of these ABC proteins. The predicted
topology of TAP1 indicates a model which spans the
membrane eight times, with several large loops ex-
posed in the lumen of the endoplasmic reticulum
[78]. At least two conformations with ‘two times
four’ or ‘two times six’ TMS have been described
for Pgp, where the four domains are fused {MD-
ABC-MD-ABC} to form a single polypeptide
[79,80]. Based on L-lactamase fusions, a topology
for HlyB indicated eight TMS [81] which deviated
signi¢cantly from that predicted simply by algo-
rithms, both with respect to number (6) and position-
ing of some TMS. A subsequent study [82] using L-
galactosidase and alkaline phosphatase also gave
eight TMS with some deviation in their precise posi-
tioning. Finally, a uni¢ed model combining this data
was devised [83], which also maximises the use of
hydrophobic residues to determine the limits (21 res-
idues) of speci¢c TMS. The overall result gives a
model with eight TMS, but still with signi¢cant de-
viation of the position of TM4 and TM6 from that
predicted from the hydropathy. TM1 and 2 in HlyB
are not predicted by most algorithms and reside in
an N-terminal which is extended compared with oth-
er type I ABC transporters. Moreover, TM1 at least
can be deleted without loss of function [84].
Electron microscopic (EM) images of Pgp 2D crys-
tals are still the only structural information available
for any intact ABC transporter [85]. The EM images
resolved to 2.5 nm reveal a possible four-domain
MD-ABC-MD-ABC assembly, but a clear structural
model for Pgp remains elusive. At this resolution it
was not possible to resolve many features of the
MDs and the two asymmetric lobes on the cytoplas-
mic side of the molecule could only tentatively be
labelled as the ATP-binding domains. A strikingly
evident feature of the structure, however, is the ex-
istence of a large crater with a diameter of 2.5 nm,
apparently narrowing to ¢nally close within the lipid
bilayer, presumably formed by the MD domains.
This proposed translocation ‘pore’ or chamber is a
much larger structure than should be required for the
transport of small drug molecules across the mem-
brane and the importance of this feature for trans-
port function has yet to be demonstrated. It is gen-
erally anticipated that ABC transporters, with
similarly organised membrane domains and a highly
conserved ABC-ATPase domain, will function in a
similar way, with the binding of the allocrite stimu-
lating ATPase action. This in turn is coupled to
movement of the allocrite across the membrane, in-
volving conformational changes in the membrane do-
main. This similarity in function might therefore be
expected to be re£ected in the overall modular design
exempli¢ed so far by the Pgp structure. Despite this,
however, is it really possible to make a functional
comparison between multidrug and protein trans-
porters, given that each transporter deals with ex-
tremely di¡erent allocrites, unrelated in size? This
is discussed in the next section.
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4.3. Can the molecular mechanism for the secretion of
drugs and proteins be the same?
Functional studies with ABC type I exporters at
the molecular level have been slow in developing,
most likely due to technical di⁄culties in puri¢cation
of the component parts. For the haemolysin system,
this has in part also been due to di⁄culties in over-
expression and even detection of the HlyB protein by
Western blotting of SDS-PAGE gels. Thus, the ad-
dition of other detergents in the SDS-sample bu¡er is
necessary to prevent aggregation of the protein, al-
lowing its entry into the acrylamide gel (J. Young,
1999, Thesis, unpublished data). ATPase activity has
been demonstrated for an HlyB-ABC-GST fusion
[86] and for the ABC domains of intact PrtD [87]
and HlyB (this laboratory unpublished), indicating
that the ATPase can function separately from the
auxiliary proteins that form the rest of the secretion
complex. Limited functional studies of PrtD in mem-
brane vesicles or after puri¢cation have met with
moderate success so far. Surprisingly, addition of
the secretion signal peptide for the PrtD allocrite
inhibited ATPase activity, which may re£ect an abor-
tive reaction in the absence of the auxiliary proteins
[87].
Although studies of the ATP cycle and the mech-
anism of allocrite recognition and binding sites have
been limited with ABC polypeptide transporters of
bacterial systems, these important aspects have been
extensively studied for cystic ¢brosis transmembrane
conductance regulator protein (CFTR), Pgp and its
homologues. The use of sophisticated tools such as
labelled drug analogues that display changes in £uo-
rescence when in a lipid membrane or aqueous envi-
ronment, have resulted in several detailed proposals
for how drugs are recognised, acquired and passed
through the transporter [61,88,89]. In relation to at-
tempts to extrapolate these results to the transport of
proteins by type I ABC exporters, it is necessary to
emphasise two main di¡erences between these sys-
tems. Small hydrophobic drugs in general partition
spontaneously into lipid bilayers and so probably
approach the transporter ‘laterally’ from the inner
lea£et of the bilayer. Large proteinaceous allocrites
like HlyA probably approach the transporter ‘hori-
zontally’ from the cytoplasm. Thus, such di¡erent
allocrites must traverse the membrane by two quite
di¡erent transport pathways despite the presumed
similar basic design of the respective ABC transport-
ers involved. The proposal that Pgp acquires its al-
locrites from the membrane is supported from data
using £uorescent analogues and interestingly the EM
structure described by Rosenberg et al. indicates the
presence of a cleft open laterally to the membrane
bilayer [85]. Finally, it is not out of the question that
drugs are transported from the inner lea£et of the
lipid bilayer to the outer lea£et or the exterior by
transport along the outside of the MD via the
TMS-lipid interfaces, thus avoiding completely the
proposed interior aqueous pore of the Pgp [89,90].
The current hypothesis for the transport of large,
relatively hydrophilic proteins, such as HlyA, envis-
ages that they may traverse an interior, aqueous
chamber of the transporter complex. If this is true,
the molecular mechanism and the transport pathway
for the secretion of drugs and proteins will ultimately
be shown to be di¡erent. Integral to this issue is the
problem of allocrite recognition by the ABC trans-
porter. It is still probable that the initial binding
site(s) for both proteins and drugs resides within
the membrane domain, albeit at topologically dis-
tinct sites. However, evidence also exists to suggest
that the ABC domain may also (directly or indi-
rectly) participate in interactions with the allocrite
[23,91]. With respect to drug transporters, a long-
standing problem has been what single feature of
the exporter complex might recognise such a wide
variety of allocrites. This is still unclear; however,
a comparable situation with the transcriptional acti-
vator, BrmR from B. subtilis, which also responds to
a variety of drug molecules, has recently been illumi-
nated with publication of the crystal structure [92].
The structure deduced also in the presence of a drug
molecule indicates a mechanism for drug induced
local unfolding of the protein to allow the drugs to
enter a hydrophobic pocket, apparently capable of
accommodating di¡erent molecules.
5. The allocrites of type I systems
Novel classes of allocrite and their corresponding
secretion systems have recently come to light in di-
verse genera (see Fig. 1). Thus, the bifunctional
S-layer-RTX-toxins secreted by Caulobacter sp. con-
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sist of an N-terminal S-layer protein fused to a C-
terminal domain containing the secretion signal and
RTX motif [93^95]. Other newly de¢ned sets of type
I allocrites are cell-associated exopolysaccharide
(EPS) processing enzymes named as ExsH, PglA
and PglB of R. meliloti, SpsR of Sphingomonas sp.
and Egl of Azorhizobium caulinodans [96,97]. PglA,
PglB and SpsR do not contain RTX repeats, possess-
ing instead novel heptapeptide repeats that may be
involved in the formation of a L-helix structure. Egl
has yet another type of repeat motif thought to form
a di¡erent fold to that formed by the RTX motif but
still involved in the binding of calcium. Thus, a re-
curring theme of allocrites passing through type I
systems is the existence of internal repeats. It remains
to be determined if the di¡erent classes of the repeat
motif contribute to secretion through the transport
apparatus and/or re-folding of the allocrite as it
emerges on the cell surface.
6. The diverse roles of ABC-dependent secretion
systems
The best characterised type I systems are the pro-
totype Erwinia chrysanthemi protease and the E. coli
haemolysin secretion systems, typi¢ed by the trans-
port complexes, PrDEF and HlyBDTolC respectively
[98,99]. Type I systems are not, however, only in-
volved in the secretion of virulence factors, but ex-
tend to much wider roles related, for example, to the
phenomena of development, gliding and swimming
in diverse Eubacteria. Examples of the latter are ¢l-
amentous cyanobacteria are Gram-negative bacteria
with a complex life cycle characterised by behaviou-
ral manifestations, such as social motility. The DevB-
CA exporter was recently identi¢ed in Anabaena sp.
which form nitrogen ¢xing, heterocysts. This ABC-
exporter complex secretes a component that is essen-
tial for the assembly of the thick laminated layer
formed on the cell surface of this Gram-negative
bacteria [71]. In relation to motility in the cyanobac-
terium, Phormidium uncinatum, a type I system is
probably involved in the secretion of oscillin, a
Ca2 binding RTX glycoprotein that has an impor-
tant role in the locomotion of this organism. Oscillin
forms an array of parallel ¢brils on top of the S-layer
and acts as a platform for the assembly and attach-
ment of carbohydrate ¢brils that guide the rotation
of the bacterium [100]. Based on homology searches
of the non-redundant protein database, type I sys-
tems can be predicted to be present in several species
including the fresh water cyanobacterium Synecho-
cystis sp., the soil bacterium Sphingomonas sp., the
hydrogenobacterium Aquifex aeolicus and the spiro-
chete Treponema pallidum [101]. Thus, type I secre-
tion pathways are polyphyletic and more widespread
than originally thought.
The presence of type I secretion systems in Gram-
positive bacteria further demonstrates the universal-
ity of this mechanism of transport which in Gram-
negative bacteria is adapted to span the periplasm
between the inner and outer membrane. One can
consider that secretion across the thick negatively
charged peptidoglycan outer layer of Gram-positive
bacteria will pose equally di⁄cult problems to those
generated by the double membrane of Gram-negative
bacteria. Type I exporters are in fact prevalent in
LAB, Gram-positive bacteria adapted to dairy envi-
ronments. Interestingly, this is the same genera in
which complex ABC multidrug transporters have
been identi¢ed such as LmrA. LAB type I systems
are concerned with the secretion of non-lantibiotics
and competence stimulating peptides (Table 2).
It is interesting to ask why the secretion of non-
lantibiotics (e.g. lactococcins, plantaricins) in LAB
involves an ABC transporter requiring an MFP ac-
cessory protein, while the lantibiotics (e.g. subtilin,
nisin, lacticins) are transported by a single ABC
transporter? The need for an accessory protein in
the case of the non-lantibiotics suggests that the
MFP proteins could have a special role in relation
to the transport of these particular peptides. These
alternative pathways may be the consequence of the
di¡erent mode of action and accompanying immun-
ity systems, associated with the two classes of bacter-
iocins [53,56]. Thus, lantibiotics are proteolytically
activated after secretion by a membrane associated
protease and act by forming pores in the cytoplasmic
membrane of target cells, without the need for a
membrane-associated receptor. LAB, which produce
lantibiotics, possess a lantibiotic host protection
mechanism that is based on an ABC transporter
(see Section 3.4). This acts at the level of the cyto-
plasmic membrane, presumably keeping the concen-
tration of lantibiotic below a critical level necessary
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for the appearance of pores. Non-lantibiotics, (e.g.
lactococcins), however, are proteolytically activated
during their transport through the cytoplasmic mem-
brane and rely on a speci¢c membrane receptor in
target cells for their pore-forming action. Other
mechanisms of self-protection appear to operate in
these examples, although detailed information is not
available. It is thought that the immunity protein
interacts with the non-lantibiotic before it can reach
the membrane or acts indirectly, binding to the mem-
brane receptor used by the antibiotic [102]. The type
I transport system is perhaps crucial for directing the
active non-lantibiotics through and away from the
cytoplasmic membrane, contributing towards a pro-
tection function in the susceptible LAB producer,
since this also produces the receptors.
Type I secretion systems (ABC-dependent) have
also been identi¢ed in Gram-positive genera other
than LAB. These are responsible for bacteriocin ex-
port in Enterococcus faecalis, and in the organisation
of ¢mbrial tufts in Strepotococcus crista. Moreover,
several examples are encoded in the B. subtilus ge-
nome, but are of unknown function [101].
Presumably, association of two protein partners
MD-ABC, MFP and an OMF in Gram-negative
bacteria is the optimum architectural answer for ob-
taining e⁄cient transport across a protective barrier
with minimum lateral leakage into the periplasm
[103,104]. We will now take a brief look at the aux-
iliary proteins associated with the ABC transporter
of type I secretion systems, noting that both the
MFPs and OMFs are sets of highly divergent pro-
teins united by a common function.
7. The auxiliary proteins of type I ABC secretion
systems
7.1. MFPs
The members of the MFP (membrane fusion pro-
tein) family of proteins were initially identi¢ed based
on similar size and predicted structural features, to-
gether with some weak sequence similarities [62] (see
Fig. 2). The MFP proteins can be subdivided into
di¡erent classes, clustering according to the type of
inner membrane component with which they associ-
ate and then according to the allocrite transported
[63]. MFPs of ABC-dependent secretion systems are
absolutely essential for the secretion of allocrites and
in their absence, the allocrite remains in the cyto-
plasm and does not accumulate in the periplasm.
This suggests that the MFP is an integral component
of the transporter complex intimately linked to the
Fig. 2. Schematic representation of the major features of HlyD, a prototype MFP protein. Above are amino acid residue numbers
from the N-terminal (left). The transmembrane domain is represented as a black rectangle; segments predicted (Pred Prot) to form K-
helices of 10-residues or more, hatched rectangles; probable L-sheet domain, horizontal lined oval; coiled-coil motif [105], vertical
striped box. The split motif of the conserved lipoyl/biotin ‘swinging arm’ [138] is represented by the two broken line boxes. The ro-
man numerals below identify di¡erent domains of HlyD deduced on the basis of similarity plots with other members of the HlyD
family (A. Pimenta, M.A. Blight, I.B. Holland, unpublished); regions II, IV and V are the most conserved. Residues from the TMD
to the C-terminal are periplasmic.
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ABC transporter, probably in order to provide a
continuous transport pathway across the periplasm
or peptidoglycan to the cell surface.
MFP proteins are anchored in the cytoplasmic
membrane by a single N-terminal transmembrane
region or for one subclass of MFP, via a lipid moi-
ety. All MFPs are likely to form coiled-coils, charac-
terised by the presence of several heptad repeat se-
quences (abcdefg)n in the extracellular/periplasmic
domain [105]. The role of this structure in relation
to the function of MFPs remains speculative, but
could include an extensible/retractory capacity simi-
lar to that of contractile proteins. Coiled-coil do-
mains are not only implicated in protein dynamics,
however, they can also be regions for subunit oligo-
merisation as in the ¢brous proteins. Interestingly, in
silico analysis of the coiled-coil segments of MFP
proteins using the multimeric prediction program
MultiCore (http://ostrich.lcs.mit.edu/cgi-bin/multi-
coil) predicts the formation of a two- rather than a
three-stranded intra- or intermolecular coiled-coil
multimerisation unit (unpublished observation).
A subfamily of the MFP family is represented by
HlyD and its homologues present in both Gram-neg-
ative and Gram-positive bacteria. The HlyD subfam-
ily is de¢ned by a consensus protein signature located
at the extreme C-terminal end of these proteins (Pro-
site entry PS00543; [106]). Although speculation as
to the possible role of this motif includes involve-
ment in an interaction with the OMF protein, its
presence in HlyD-like proteins of Gram-positive bac-
teria, which lack an outer membrane discourages this
view. Pertinently, HlyD-like proteins of Gram-posi-
tive bacteria possess extracytoplasmic domains of a
similar length to those of the larger MFPs of Gram-
negative bacteria. The peptidoglycan-traversing do-
main of MFPs do not contain recognised consensus
sequences involved in protein^cell-wall anchoring or
association, unlike proteins such as MotB of the £ag-
ellar motor [107]. This could suggest that the trans-
envelope MFPs need to be £exible rather than rigid
in structure. Despite the fact that several MFP pro-
teins of Gram-negative bacteria function with the
same OMF, TolC, it is not evident from simple se-
quence gazing that a common sequence, involved in
an interaction with TolC, can be identi¢ed. Thus, the
interaction, if it exists, probably relies on conforma-
tion rather than a speci¢c amino acid sequence.
7.2. OMFs
In Gram-negative bacteria, an additional auxiliary
protein is required for the transfer of allocrites across
the outer membrane [61]. These OMFs probably
work in conjunction with the MFPs (Table 2). Two
dimensional crystallography of the best characterised
representative, TolC, showed two globular modules,
a membrane-embedded moiety and a substantial ex-
tra-membrane domain proposed to extend down into
the periplasm [108]. Two di¡erent models have been
proposed for the topology of TolC. One model based
on a particular algorithm favours the formation of
an 18-stranded L-barrel transmembrane domain with
a C-terminal periplasmic domain [108]. However,
specialist prediction methods involving intelligent
neural networks trained and tested on multiple align-
ment sets make a strong case for transmembrane
L-strands dominated by substantial amounts of K-
helical structure in TolC [101]. This makes it unlikely
that the OMFs adopt a L-barrel fold, rather a mixed
K/L fold unlike any other OM protein of known
structure. At least six K-helices adjacent to the pre-
dicted L-strands are predicted, all with high coiled-
coil probability. In this second model, the coiled-coil
domains self-associate into a helical bundle predicted
to correspond to the periplasmic domain. Both mod-
els agree that the OMFs are quite distinct from the
porins bearing no sequence similarity and an extra-
membrane domain that could contribute towards
forming a trans-periplasmic channel and/or be in-
volved in interactions with the MFP or ABC trans-
locator components. Based on gel ¢ltration experi-
ments and 2D images of TolC, it appears that the
OMFs trimerise [108]. However, it was not possible
from the 2D images at 1.2 nm resolution to deduce
whether three TolC monomers form a central pore or
alternatively whether each subunit forms a pore.
A further general feature of the OMFs includes a
tandem symmetry of the N- and C-terminal halves of
these proteins [101,109]. This suggests that the OMFs
arose by an intragenic duplication event and that the
two halves of these proteins show a similar confor-
mation. In most of the type I secretion systems, the
genes encoding the ABC-MFP exporter are linked to
the gene encoding a speci¢c OMF constituent. In
cases such as the haemolysin secretion system, the
gene for the OMF is not linked and tends to be
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multifunctional, participating in a variety of interac-
tions and receiving numerous translocating allocrites
for both import and export [39,110^112]. Presum-
ably, therefore, the OMF is not involved in allocrite
speci¢city with respect to the type I system.
8. The logistics of type I transport
There are many fascinating questions to be posed
concerning the type I secretion mechanism to which
a brief allusion is made here. In Gram-negative bac-
teria, the allocrite has never been detected in the
periplasm. For this reason, the transport pathway
is referred to as a one-step secretion process, indicat-
ing transport of the allocrite directly from the cytosol
to the external environment (Fig. 1). This could be
achieved in two ways depending on the action of the
MFP. MFPs may reduce the spatial separation be-
tween the extracellular surface and cytoplasmic mem-
brane by bringing the two into close proximity. In
Gram-negative bacteria, this could occur through in-
teractions of the MFP with the inner and outer mem-
brane protein components of the secretion apparatus.
It is not clear how a comparable e¡ect could be
achieved in the case of the rigid external peptidogly-
can layer of Gram-positive bacteria. Alternatively,
MFPs may provide a channel across the periplasm
and the peptidoglycan allowing molecules to reach
the cell surface directly.
The periplasmic compartment of Gram-negative
bacteria has an estimated depth ranging from 13 to
25 nm and contains a thin single-layered peptidogly-
can [104]. Biophysical measurements of a functional
version of the MFP protein, AcrA, consisting of just
the periplasmic domain, predicted its length to be
about 17 nm, agreeing with the prediction that these
proteins can form extended molecules capable of
spanning the periplasm [113]. If the MFP proteins
do form a transenvelope pipeline, what could be
the nature of the structure? Is it closed or permeable
to the non-reducing redox environment of the peri-
plasm. Two observations in fact suggest that the al-
locrite is not completely isolated from the periplasm.
The operons of type I systems that secrete proteases
also encode a speci¢c protease inhibitor, presumably
for protection against intracellular proteolytic activ-
ity. Surprisingly, the inhibitor, unlike its cognate pro-
tease is exported via the Sec system and N-terminal
signal sequence, to the periplasm. Consequently, its
ability to prevent the action of the protease, if this is
secreted via an independent, physically separate
route is rendered redundant, unless the inhibitor
can access the allocrite during transit. This paradox
remains unresolved [114]. Secondly, the 9-kDa allo-
crite, Colicin V, is di-sulphide bonded, while most
other allocrites of type I systems are cysteine-less,
as are the periplasmic domains of the MFPs. In the
case of colicin V, the formation of di-sulphide
bridges also implies that this protein passes through
the periplasm accessible to enzymes like DsbA.
In relation to possible discrete translocation path-
ways for type I proteins, it is interesting to contem-
plate what volume, for example, the 107-kDa HlyA
molecule would occupy within the periplasm or with-
in a transenvelope channel? The answer depends on
whether the allocrite is transported in a completely
or partially folded or unfolded state during translo-
cation. In the cytoplasm, it is presumed that the al-
locrites, characterised in most cases by a C-terminal
signal sequence, are presented to the transporter
post-translationally but ‘unfolded’. Free calcium con-
centrations available in the cytoplasm are too low to
allow folding of the RTX Ca2-binding repeat motif.
Cytosolic chaperones have been reported to partici-
pate in the type I secretion process, for example in
HlyA transport (J. Whitehead and J.M. Pratt, per-
sonal communication) and HasA, although notably
not containing a glycine-rich repeat, appears to re-
quire SecB for transport [115]. Furthermore, two
members of the bacteriocin family can be transported
by the core Sec machinery of E. coil when fused to
the appropriate signal peptide, suggesting that the
peptides remain su⁄ciently unfolded for acceptance
by the Sec-machinery prior to translocation
[116,117]. Participation of a chaperone is evidence
that the allocrite is maintained unfolded prior to
transport.
Several type I C-terminal secretion signal peptides
have been subjected to CD and NMR spectra and
shown to be highly £exible and unstructured in aque-
ous solution and sometimes even in membrane mim-
etic environments [70,115,118,119]. Although some
secondary structural features are predicted in the
C-terminal secretion signals of type I allocrites, their
importance to the transport process is questionable
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since secretion levels are una¡ected by even major
mutational changes predicted to disrupt secondary
structure. Thus, the secretion motif recognised by
the apparatus is probably contained within an un-
structured sequence dependent on a few dispersed
key residues [120]. A relatively unstructured secretion
sequence, whose speci¢city is determined by the pat-
tern of a few side chains, is reminiscent of the pro-
posed mechanism for the recognition of the major
histocompatibility (MHC) class I peptides by the
HlyB homologue, TAP1/2 [75]. Such a mechanism
could explain the lack of strong conservation of the
type I secretion signal and the relative promiscuity of
the secretion apparatus. This is particulary well illus-
trated by the versatile E. coli K-haemolysin (HlyA)
secretion apparatus HlyBD,TolC, recognising more
than 400 heterologous proteins fused to the C-termi-
nal signal sequence, but otherwise unrelated to HlyA
[121]. It is this property that permits its potential use
for the presentation and delivery of antigens to the
immune system in bacterial vaccine carriers [122].
What happens to the allocrite during the secretion
process remains a black box of possibilities, for the
moment limited only by the imagination. For exam-
ple, can the RTX repeats, characteristic of type I
allocrites, bind calcium during transit through the
aqueous periplasmic compartment, thought to be
rich in divalent cations, since this communicates
with the cell exterior [123]. How can the relatively
hydrophilic allocrite access the hydrophilic cell sur-
face for ¢nal release? The energetics of the translo-
cation process across one or two membranes are also
not well understood. Are the allocrites pushed and/or
pulled directly to the extracellular space only by the
energy of nucleotide hydrolysis carried out by the
ABC transporter? The one relevant study performed
using the haemolysin secretion system suggests secre-
tion is both ATP and pmf dependent, but occurs
through consecutive steps that di¡er in energetic de-
mand [124]. One possibility if the kinetics of secre-
tion are very fast [125], is that unfolding, followed by
refolding of the allocrite is promoted by the trans-
porter itself in conjunction with, for example LPS
and Ca2. In addition, from recent results involving
both HlyA mutants with an altered secretion signal,
and mutations in HlyD, indicate that correct folding
of the HlyA molecule is a¡ected ([126], A. Pimenta
and J. Young, unpublished), we conclude that HlyA
must at least be partially unfolded during transloca-
tion. In that case, the re-folding reaction itself, pre-
sumably catalysed by surface Ca2 binding to and
stabilisation of the C-terminal RTX-L strand struc-
ture, could contribute to the ¢nal stages of translo-
cation coupled to the release of the toxin. Interest-
ingly, similar re-folding steps involving Ca2 appear
to be implicated in secretion of subtilisin from B.
subtilis and in the secretion to the endoplasmic retic-
ulum of several proteins [127,128].
Recently, the attention of several laboratories has
focused on the structural organisation of the type I
translocator complexes and its relationship to the
allocrite. This is a sensible prerequisite to under-
standing the mechanism of how ABC secretion sys-
tems work. The approach used has concentrated on
the identi¢cation of protein^protein interactions, us-
ing a variety of methods, reaching so far some di¡er-
ent, even con£icting conclusions. The aim of this last
section is to review these new data and summarize
how they either support or contradict the relevant
transport concepts. Much of this work has concen-
trated on the prototype Hly and Prt transporters as
model systems.
9. Identifying protein^protein interactions
9.1. Molecular genetic approaches
9.1.1. Hybrid transporters
Exploiting the di¡erence in the broad spectrum of
allocrites secreted by two type I exporters, Wanders-
man and colleagues attempted to identify which pro-
tein element was involved in initial recognition of the
allocrite [129]. Di¡erent combinations of ABC-MFP-
OMF constituents from two translocators were ex-
pressed and the £exibility of the hybrid exporter
tested for secretion of given allocrites in vivo. It
was found that co-expression of the allocrite and
its own ABC transporter, dictated whether the allo-
crite was secreted or not, thus providing evidence
that at least some speci¢city for initial recognition
of preferred allocrites resides in the ABC-ATPase
containing component. However, the interpretation
of such experiments is rather limited, since the actual
step (early or late) which is blocked in translocation
is unknown. Moreover, these studies do not exclude
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the possibility that the MFP could be playing a role
in conjunction with the ABC transporter in initial
recognition of the allocrite. In a related paper, Akat-
suka et al. [130] describe mutations in an ABC trans-
porter, capable of secreting two di¡erent allocrites,
which abolished the secretion of one but not the
other allocrite. Unfortunately, these mutations were
not characterised. Further pair-wise swapping of het-
erologous type I exporter subunits showed that the
various components are not universally interchange-
able. The results clearly demonstrated that the MFP
can associate with a certain ABC transporter, whilst
the OMF is speci¢c for a certain MFP in order to
produce a functional transporter. Importantly, the
deduced, preferred protein interactions, generally
agree with phylogenetic analyses. The next logical
step is to make use of chimaeric molecules of a single
translocator component and determine the region
within the chimera that allows secretion from one
heterologous translocator, but not another. This
type of experiment would help assignment of speci¢c
functions to protein domains and indicate more pre-
cisely areas of interaction between protein compo-
nents. In this way, we may hope to solve the puzzle
of allocrite speci¢city combined with appropriate
structural studies.
9.1.2. Suppressor studies
Vancomycin is an antibiotic which a¡ects the bio-
genesis of the peptidoglycan in Gram-positive bacte-
ria through binding to a cytoplasmically synthesised
peptidoglycan precursor [131]. With a molecular
weight of 1.4 kDa, vancomycin is too large to pene-
trate e⁄ciently the outer membrane barrier of E. coli
through the porins. However, cells expressing the
Hly translocator are sensitive to vancomycin and
even more so in the presence of HlyA [84,132].
Schlor et al. [133] exploited the toxic e¡ects of van-
comycin to classify secretion defective HlyD mutants
as conferring increased or decreased sensitivity to
vancomycin. Since the sensitivity to vancomycin as-
sociated with various combinations of HlyB and mu-
tants of HlyD was dependent on the presence of
TolC, the authors concluded that HlyD can directly
interact with TolC, but only in the presence of HlyB.
The change in the sensitivity of E. coli to vancomycin
caused by speci¢c mutations in HlyD, was not de-
pendent on HlyA. This suggested an interaction of
the HlyBD,TolC complex even in the absence of the
allocrite. Next, these authors selected for strains that
simultaneously restored HlyA transport and sup-
pressed vancomycin hypersensitivity, caused by a sin-
gle missense mutation at the extreme C-terminal of
HlyD (residue 477 out of 478). Three suppressors
were localised to the periplasmic domain of HlyD
(residues 362, 392, 441) and one suppressor mutation
changed Pro-313 to Ser or Lys in HlyB. Although
none of the mutations were shown to be allele spe-
ci¢c, the isolation of intra- and intergenic suppressor
mutations provides evidence for regions of HlyD and
HlyB which interact. Based on their results, Schlor et
al. [133] proposed an original model for HlyD inter-
acting with both the ABC transporter and the OMF,
showing the MFP folding back on itself at a poten-
tial gap between the coiled-coil regions, thus placing
the C-terminal end of HlyD near to the inner mem-
brane.
9.2. Biochemical approaches
9.2.1. A⁄nity chromatography
Co-a⁄nity chromatography is an increasingly pop-
ular method for demonstrating protein^protein inter-
actions; however, results should be interpreted with
extreme caution, especially when dealing with hydro-
phobic membrane proteins. The technique assumes
that detergent solubilised proteins retain their overall
structure and moreover maintain normal associations
throughout the solubilisation, wash and elution
steps. Rigorous controls must be included to ensure
that the putative interactions identi¢ed are not arti-
facts of the procedure itself. Le¤to¡e¤ et al. [134] de-
scribe the extraction of the entire metalloprotease
(PrtDEF) exporter dependent upon association with
two non-translocatable allocrites: a⁄nity-tagged
GST-PrtC which can be bound to glutathione-seph-
arose and HasA, retained by haem-agarose. Sub-
sequent co-a⁄nity puri¢cation experiments per-
formed with incomplete or hybrid translocator
components, led the authors to favour an ordered,
sequential assembly of the translocator, i.e. the ABC
transporter binds the MFP which then interacts with
the OMF. The rationale behind these experiments is
that the strength of the interaction of the transloca-
tor components is increased by the presence of the
allocrite, presumed to be stuck in the translocator,
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since it is not secreted. Unfortunately the value of the
study is somewhat undermined by the absence of
physical evidence to authenticate the presence of a
stuck intermediate. Although the conclusions
reached by the authors are not necessarily wrong, it
seems improbable that three layers of non-covalent
protein interactions could be maintained during iso-
lation of envelopes followed by solubilisation from
the envelopes. The negative control used in these
experiments, simply the absence of allocrite, is insuf-
¢cient and a more prudent control would have been
a dummy co-puri¢cation of the translocator using
the allocrite minus the a⁄nity tag, thus keeping the
same ionic charge and bulk conditions. As pointed
out by the authors themselves, a higher proportion
of the translocator proteins remained unbound than
was retained by the a⁄nity matrix via the non-trans-
locatable allocrite, present in excess. In addition,
when the ¢nal extract bound to the glutathione beads
was analysed by SDS-PAGE and Coomassie blue
staining, other contaminating proteins were visible
while the translocator proteins themselves were de-
tected by immunoblotting. In summary, in the ab-
sence of more controls can we be sure that authentic
complexes were isolated in this study.
9.2.2. Measurements of protein stability
In the colicin V secretion system (CvaBA,TolC),
the stability of the ABC transporter and the MFP
was studied in the absence of the other partner, or in
the absence of TolC [135]. The results indicated a
mutual stabilisation of the ABC transporter and
MFP. Using the same procedure for measuring pro-
tein half-life, comparable results were obtained for
HlyD, the MFP of the Hly translocator [136]. How-
ever, in the experiments of Hwang et al. [135], the
stability of the MFP in the absence of the ABC
transporter and TolC was not tested. Under these
conditions, Pimenta et al. [136] showed that the in-
stability of HlyD, induced by the absence of TolC,
was greatly reduced when HlyB was also absent. In
other words, the absence of TolC per se does not
a¡ect the stability of the MFP component, unless
the ABC transporter, HlyB is also present. This sug-
gested that the ABC transporter is a determinant of
HlyD stability and moreover the results provided
evidence for at least two topological or organisation-
al states of the MFP, dependent upon the presence
or absence of the ABC transporter, as re£ected by
protease sensitivity. Thus, HlyB labilised HlyD to
endogenous proteases (relative to its stability alone
or in the presence of TolC), while the combined pres-
ence of HlyB and TolC rendered HlyD extremely
stable to proteases. Both states of HlyD were shown
to be independent of the presence of the allocrite.
Interestingly, none of these data indicated an inter-
action between the MFP and TolC, except again in
the presence of the ABC transporter.
9.2.3. Cross-linking
Hwang et al. [135] also published the ¢rst in vivo
cross-linking results involving components of a type I
secretion system. Using formaldehyde as a cross-link-
ing reagent, putative interactions were proposed,
based on the recognition of the cross-linked com-
plexes with antibodies directed against speci¢c trans-
locator components. An MFP:MFP dimer interac-
tion was substantiated by further experimentation
and this multimerisation was shown to be independ-
ent of the presence of the allocrite. In this laboratory,
recent studies have demonstrated co-a⁄nity puri¢ca-
tion of HlyB and HlyD and HlyB with HlyA. In
addition, both genetic studies and cross-linking
with DSP has clearly shown the presence of higher
molecular weight homo- oligomers of HlyD, at least
up to trimers, whose formation depends upon the
presence of a fully assembled translocator but not
HlyA (J. Young, 1999, Thesis; J. Young et al., in
preparation).
Using a combination of cross-linking with DSP
and co-a⁄nity puri¢cation, Thanabalu et al. [137]
isolated and dissected protein interactions in the
HlyA system. In this case, the ABC transporter
and MFP of the Hly translocator were a⁄nity-
tagged, rather than the allocrite, as in the experi-
ments of Le¤to¡e¤ et al. [134], using the Prt system.
Thanabalu and colleagues reinforce the ¢ndings of
the stability experiments con¢rming the presence of
ABC transporter:MFP inner membrane complexes,
independent of TolC and the allocrite. New associa-
tions of proteins were also identi¢ed including an
intriguing interaction of the MFP with the allocrite,
in the absence of the ABC transporter. This is in
contradiction to the idea of sequential interactions
induced in response to allocrite binding to the ABC
transporter [134]. However, the former result could
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be attributed to the fact that cross-linking was used,
thus stabilising weaker interactions that might have
gone undetected by other methods. This result more-
over is consistent with results from this laboratory
(A. de Lima Pimenta, PhD thesis, 1995, unpublished)
that the MFP may play a role from the earliest point
in the translocation pathway. Again, in this study, no
evidence was found to suggest an interaction of the
OMF with the MFP, except in the presence of the
ABC transporter.
Notably, the presence of the allocrite was required
for isolation, after DSP cross-linking, of the three
protein translocator complex, as previously suggested
by the Wandersman laboratory [134]. Interestingly,
the three components of the translocator could still
be cross-linked and co-puri¢ed in the presence of an
ABC transporter that possessed a mutation render-
ing the ABC transporter defective in ATP hydrolysis,
allocrite secretion, but obviously not allocrite recog-
nition. This suggests that the type I secretion appa-
ratus is a self-assembling structure, not requiring hy-
drolysis of ATP. Increased protease accessibility of
the exporter components during secretion was also
noted by Thanabalu et al., suggesting speci¢c con-
formational changes accompanying transport of the
allocrite. The conclusion was also reached that the
translocator complex was apparently transient, dis-
assembling after translocation. The authors in addi-
tion investigated the subunit stoichiometry of the
MFP component using a di¡erent cross-linker,
DSG. From this they provide evidence that HlyD
could apparently self-associate to form trimers in
the absence of its cognate translocator components.
Based on their large number of ¢ndings, Thanaba-
lu et al. [137] favour the idea that the haemolysin
translocator consists of a contiguous rather than a
continuous channel. They present their view of the
translocator with an interesting ‘shuttle’ mechanism
whereby the transenvelope translocator is capable of
opening at one end or the other but not simultane-
ously. The allocrite can accumulate in the ¢rst cham-
ber before being moved to a second chamber imag-
ined to be closed to the cytoplasm but open to the
external medium. An attractive feature of the model
is that it provides a solution to the problem of gating
an open channel which would otherwise lead to leak-
age of cell contents. TolC is thought not to be a
gating protein since it forms ion-channels in planar
lipid bilayer membranes, although the size of the
channels was reported to be reduced upon addition
of a soluble periplasmic domain of HlyD in vitro
[133]. In the discontinuous transenvelope channel
model, gating is apparently provided by controlled
opening of a chamber formed by HlyB and HlyD
combined and regulated by ATP hydrolysis in re-
sponse to allocrite binding. Interestingly, from our
own genetic analysis of HlyD we have come to sim-
ilar conclusions, with, however, HlyD itself possibly
capable of forming two contiguous chambers (A. de
Lima Pimenta, J. Young, M.A. Blight, I.B. Holland,
unpublished).
9.3. In silico analysis
Complementary to the biochemical and genetical
experiments described above, it is useful to include
within this review some insights gained from bioin-
formatics, concerning the possible structure and
function of the MFP component of the translocator.
As part of an ongoing genetic analysis of the func-
tion of HlyD we have included a detailed analysis of
the structure of HlyD and its homologues (Fig. 2).
One novel idea arising from this analysis and from
published and unpublished data is that MFPs are
£exible dynamic proteins, with a global conforma-
tional change or reorganisation of the protein with
respect to multimerisation, being required for allo-
crite transport. This implies radical upgrading of
the MFP’s involvement during secretion. This is
based on the presence of a coiled-coil helical domain
centrally located in the primary sequence [105], con-
ceivably involved in the formation of the oligomers
of HlyD described above. In addition, we have iden-
ti¢ed a motif on each side of the coiled-coil pattern
with homology to a half-set of a lipoyl and biotin
swinging arm module [101,138]. Lipoyl/biotin swing-
ing arm domains are present in certain multienzyme
complexes and are involved in a ‘swinging arm’ ac-
tion that contributes to the passing of a bound co-
factor between catalytic sites. Some NMR structures
have been solved for several lipoyl and biotin do-
mains and CD spectroscopy has been performed on
a peptide corresponding to this domain from the
MFP, MexC, that associates with a di¡erent class
of integral membrane protein other than an ABC
transporter and is involved in the e¥ux of drugs.
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Interestingly, this peptide was shown to adopt the
expected fold under certain conditions [101]. This
encouraged the hypothesis that the distantly con-
served domain to the swinging arm present in
MFPs, provides the possibility of intramolecular
movement within these molecules. Thus, the role of
the MFPs in transport may be more active than ¢rst
imagined. Such movement could contribute to the
formation of a trans-periplasmic channel. In addi-
tion, the MFP could simply harness the movement
for actual binding and passing of the allocrite from
the ABC transporter to the exterior. This active role
for the MFP is supported by the fact that HlyD can
in£uence the ¢nal conformation of the secreted HlyA
as shown by the fact that mutations in HlyD result in
the secretion of a largely inactive toxin which ap-
pears unfolded, (A. Pimenta, K. Racher, J. Young,
this laboratory unpublished).
10. Outlook
The data gathered here from a number of labora-
tories agree on several points. All provide persuasive
evidence to postulate that the ABC transporter,
MFP and OMF function together as a structural
complex, as indicated in Fig. 1 (left). Intimate asso-
ciation of the ABC transporter and the MFP in the
absence of the OMF, during and even prior to inter-
action of the allocrite has been documented. The
MFP component apparently interacts with the
OMF, but only in the presence of an ABC trans-
porter. Cross-linking experiments show that the
MFP oligomerises to form at least a trimer. One of
the most pertinent points to come out of all the data
is an in£uence of the ABC transporter upon MFP
stability and conformation. It is not clear whether
this re£ects the main role of the ABC transporter
in energising transport or whether this is an addi-
tional role. There are now well documented examples
of ABC transporters regulating the activity of a quite
distinct membrane protein. Thus, the human SUR
protein, involved in insulin regulation of K trans-
port, forms a speci¢c complex with a K channel
whose activity is controlled by the ATPase action
of SUR [139,140]. There are also reported bacterial
examples of ABC transporter ‘colateral’ interactions
with or regulation of other membrane proteins.
These include AbcA of Aeromonas salmonicida that
apparently possesses both regulatory and transport
activities. SapABCDF, an ATP-driven peptide im-
porter, regulates the activity of a potassium ion
channel in Salmonella typhimurium and Aap, an ac-
tive importer of L-amino acids, appears to in£uence
the rate of amino acid e¡ux in Rhizobium legumino-
sarum [141^143]. Extrapolating these ¢ndings to the
HlyB-HlyD couple in type I secretion leads to a nov-
el view of HlyB controlling (by an ATP-dependent
mechanism?) the opening^closing of a multimeric
HlyD transport channel connected directly both to
the cytoplasm and TolC. This alternative to the HlyB
membrane domain itself constituting a transport
pathway across the inner membrane has some attrac-
tions.
There still exist contradictions between laborato-
ries (or perhaps secretion systems?) concerning the
nature of the assembly of the type I translocator
and the necessity or not of the presence of the allo-
crite for assembly. Nevertheless, there is now accumu-
lating evidence that the type I secretion systems do
involve speci¢c complexes between an ABC protein,
an MFP and an OMF, with a possible stoichiometry
of 2, at least 3 and 3, respectively. Moreover, some
steps in the translocation pathway, involving initial
recognition by the allocrite and subsequent distinct
events in the translocation pathway, do seem to be-
coming clearer. These studies and their implications
discussed here should, we hope, provide stimulation
and guidance for further ongoing research.
Elucidation of the architecture and the dynamics
of secretion via the ABC pathway presents a formi-
dable obstacle to practical experimentation, particu-
larly in the case of the transenvelope type I structures
of Gram-negative bacteria. The usefulness of semi in
vitro systems involving isolating osmotic or pressure
shocked vesicles on sucrose density gradients is lim-
ited, since they disrupt the cell envelope together
with any transenvelope structures. Unfortunately, in
vitro systems which would allow reconstitution of the
whole pathway across the two membranes of E. coli,
as has been achieved for the Sec-translocation sys-
tem, have so far proved impossible to develop. For
this reason, it is perhaps better to apply the immu-
no£uorescence microscopy approaches used recently
in studies of supramolecular transenvelope struc-
tures, such as the type III protein secretion system
and the £agellar motor [144^146]. Understanding the
ultrastructure of the ABC secretion pathway could
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be obtained by locating the translocator proteins on
the structure by cryoelectron or immuno-electron mi-
croscopy. Copy numbers of the components could be
determined by immunoblot and 2D gel electropho-
retic analysis, con¢rming subunit stoichiometry. The
absence of a known structure for any of the mem-
brane proteins involved in the translocator is particu-
lary frustrating and crystallisation or NMR solution
structure of isolated protein domains should be in-
structive. Indications are that transport is fast and
cross-linkers and spectroscopic probes could help
document conformational changes during transloca-
tion. It should also be possible to apply other tech-
niques, such as cysteine scanning mutagenesis to the
study of the structure and function of components of
the type I secretion machinery. The development and
detailed characterisation of stuck intermediates, in-
volving modi¢ed allocrites is still not being fully ex-
ploited to dissect the type I pathway. Finally, in the
absence of a fully reconstituted in vitro system, the
puri¢cation, solubilisation and reconstitution of the
ABC and MFP components in liposomes, in order to
analyse at least the initial steps in translocation is
now urgently required.
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